Pressmeddelande

BioStock: The temperature of Cereno Scientific after major news

Cision Publicerad: 22 Oct 08:29

Cereno Scientific has recently announced the selection of a rare disease, idiopathic pulmonary fibrosis, as the target indication for its second drug candidate, CS014. Along with the new data for its lead candidate, CS1, this marks a clear shift in strategy and focus: rare diseases that today leave patients without effective treatment options. CEO Sten R. Sörensen visited BioStocks studio to talk more about this.

Watch the interview with CEO Sten R. Sörensen at biostock.se:

https://www.biostock.se/en/2024/10/the-temperature-of-cereno-scientific-after-major-news/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Nyheter om Cereno Scientific

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!